Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the impact of afamelanotide on the severity of skin
disease in patients with Variegate Porphyria (VP). The secondary objectives are to evaluate
the safety and tolerability of afamelanotide in patients with VP and evaluate the impact of
afamelanotide on the quality of life of patients with VP.